D. J. Buurman

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

Niels Vande Casteele, D. J. Buurman, Marieke G. G. Sturkenboom et al. · Alimentary Pharmacology & Therapeutics · 2012 · 207 citations

Pharmacy, Immunology, Pharmacology +17

Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease

Graham Heap, Kenji So, Naomi Edney et al. · Journal of Crohn s and Colitis · 2015 · 117 citations · Full text

Medicine, Nephrology, Pharmacology +17

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

D. J. Buurman, Jacoba M. Maurer, Ron J. Keizer et al. · Alimentary Pharmacology & Therapeutics · 2015 · 68 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

ColoPulse tablets perform comparably in healthy volunteers and Crohn's patients and show no influence of food and time of food intake on bioavailability

Jacoba M. Maurer, R.C.A. Schellekens, H.M. van Rieke et al. · Journal of Controlled Release · 2013 · 27 citations

Pharmacy, Nutrition, Nutritional Sciences +15

Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study

D. J. Buurman, Jan G.R. de Monchy, R.C.A. Schellekens et al. · Scandinavian Journal of Gastroenterology · 2015 · 10 citations

Pharmacy, Pharmacology, Pharmacotherapy +16